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ABSTRACT 
Calpains are intracellular cysteine proteases with important physiological functions. Up- or 
downregulation of their expression can be responsible for several diseases, therefore specific 
calpain inhibitors may be considered as promising candidates for drug discovery. In this paper 
we describe the synthesis and characterization of a new class of inhibitors derived from the 
analysis of amino acid preferences in primed and unprimed sites of calpains by incorporation 
of L- or D-epoxysuccinyl group (Eps). Amino acids for replacement were chosen by 
considering the substrate preference of calpain 1 and 2 enzymes. The compounds were 
characterized by RP-HPLC, amino acid analysis and ESI-MS. Selectivity of the compounds 
was studied by using calpain 1 and 2; and cathepsin B. We have identified five calpain 
specific inhibitors with different extent of selectivity. Two of these also exhibited isoform 
selectivity. Compound NH2-Thr-Pro-Leu-(D-Eps)-Thr-Pro-Pro-Pro-Ser-NH2 proved to be a 
calpain 2 enzyme inhibitor with at least 11.8-fold selectivity, while compound NH2-Thr-Pro-
Leu-(L-Eps)-Ser-Pro-Pro-Pro-Ser-NH2 possesses calpain 1 enzyme inhibition with at least 4-
fold selectivity. The results of molecular modeling calculations suggest that the orientation of 
the bound inhibitor in the substrate binding cleft is markedly dependent on the 
stereochemistry of the epoxysuccinyl group. 
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1. INTRODUCTION 
The members of calpain family are intracellular Ca2+-ion dependent cysteine proteases [1, 
2] which are present in almost all eukaryotes and also in some bacteria. The two ubiquitous 
forms are the calpain 1 (µ-calpain) and calpain 2 (m-calpain). Calpains have important role in 
various cellular activities (cell adhesion and motility, signal transduction, exocytosis and 
regulation of gene expression etc.) [3, 4, 5, 6, 7]. Over-activated calpains could be involved in 
the pathogenesis of a wide range of disorders such as Alzheimer’s, Huntington’s and 
Parkinson’s diseases, multiple sclerosis, amyotropic lateral sclerosis or ischemic and 
traumatic brain injury [8, 9]. 
Most of the peptide- and non-peptide-based calpain inhibitors interact only with Sn 
positions of the active site [10], although expanding the binding surface towards Sn’ sites may 
result in more selective inhibitors. Design of inhibitors by studying the preference of amino 
acids in certain positions of calpain substrates can be considered as a promising strategy. 
Tompa et al. analysed numerous cleavage sites in calpain substrates, and established a matrix 
containing preferences of amino acids in positions P4–P7’ [11]. Based on this matrix, a FRET 
calpain substrate with excellent characteristics, and also its cell-penetrating derivative was 
successfully prepared and applied to monitor intracellular calpain activity [12, 13]. 
Based on this substrate sequence, we have designed a group of azaglycine (Agly) 
containing analogues as potential novel calpain inhibitors [14]. In these compounds Lys in 
position P1 has been changed to azaglycine. 
The epoxysuccinyl group (Eps) can be used to design inhibitors with different amino acids 
at Pn and Pn’ sites. Some synthetic and natural peptide epoxides have already been described 
as proven cysteine protease inhibitors [15]. 
The trans-L-epoxylsuccinyl-L-leucylamido-4-guanidino-butane (E-64) was first published 
as an effective and selective cysteine protease inhibitor possessing epoxy group [16]. This 
compound and its derivatives are irreversible inactivators of cysteine proteases. Different 
parts of E-64 were varied to improve its inhibitory effect on calpains [17]. 
Using L- or D- epoxysuccinyl analogues the effect of changes in positions P4-P2 was 
studied on calpain 1 and 2 inhibition [18]. As a result of this systematic study a peptide 
analogue, WRH(D-Eps)-OEt was identified as a selective and irreversible calpain inhibitor. 
Pfizer et al. attached different dipeptides to the free carboxylic group of Ep-460 (HO-
(L)Eps-Leu-NH-[CH2]4-NH-Z; e.g. HO-AA1-AA2-(L)Eps-Leu-NH-[CH2]4-NH-Z), and 
studied the inhibitory activity on calpain 1, cathepsin B and cathepsin L [19]. Ep-460 was 
supposed to direct the dipeptide part to the primed position in the substrate binding pocket. 
The amino acid preference was examined using amino acid libraries of positions P1’ and P2’. 
Recently, Schiefer et al. reported E-64 analogues as potent calpain 1 selective inhibitors 
[20]. The capping group of E-64 (4-guanidino-butane) at position P3/P4 and Leu at position P2 
were changed. The selectivity of these compounds was characterized using papain. 
In the present paper we describe the design, synthesis and functional characterization of 
novel potential peptide inhibitors with epoxysuccinyl group of cysteine proteases calpain 1 
and 2, and cathepsin B. Molecular modeling was also performed to understand the binding of 
inhibitors with L- or D-epoxysuccinyl group. The presented peptide analogues are based on 
the sequence of calpain substrate peptide (TPLKSPPPSPR), containing different amino acids 
at positions P and P’, derived from the preference matrix [11]. By incorporation of L- or D-
epoxysuccinyl group, the amino acid preference at positions P and P’ was scanned to identify 
novel calpain inhibitors. 
 
2. Materials and methods 
All amino acid derivatives were purchased from Bachem (Bubendorf, Switzerland) and 
Reanal (Budapest, Hungary); whereas DIEA, HOBt, DIC, TFA were FLUKA (Buchs, 
Switzerland) products. Rink-amide MBHA resin was from Iris Biotech GmbH (Marktredwitz, 
Germany). Racemic trans-L/D epoxysuccinic acid was obtained from TCI (Tokyo, Japan). 
Solvents for synthesis and purification were obtained from Molar Chemicals Kft (Budapest, 
Hungary). The fluorescent substrates Suc-Leu-Tyr-AMC (catalog no. S 1153) and all other 
chemicals used in biochemical experiments were purchased from Sigma. The calpain 1 
enzyme from human erythrocytes (EC 3.4.22.52) and cathepsin B from human liver (EC 
3.4.22.1), as well as the substrate III of cathepsin B (Z-Arg-Arg-AMC x 2 HCl) were obtained 
from Calbiochem/Merck (Darmstadt, Germany). All buffers were prepared with ion 
exchanged distilled water. 
 
2.1 Synthesis of tripeptides and L- or D-epoxysuccinyl-pentapeptides 
The resolution of trans-L- and D-epoxysuccinic acid isomers using racemic starting 
material was performed as described by Tamai et al [21] without modification. Yield of 
resolution was 41% for the D-enantiomer and 46% for the L-enantiomer. The tripeptide 
segments were synthesized manually by solid phase peptide synthesis on Rink-amide MBHA 
resin (0.2 g, 0.52 mmol/g) using Fmoc/tBu strategy. The amino acid side-chain protecting 
groups were trityl for Gln and 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl for Arg. 
The side chain of Ser and Thr was protected with tert-butyl group. The Nα-Fmoc group was 
removed with 2% DBU in the presence of 2% piperidine in DMF (2, 2, 5, 10 min) followed 
by washing with DMF (8 x 0.5 min). For coupling, amino acid derivatives, DIC and HOBt 
dissolved in DMF were used in 3-fold molar excess for the resin capacity. The reaction 
proceeded at RT for 60 min, then the resin was washed with DMF. 
The epoxysuccinyl-pentapeptides were built up also on Rink-amide MBHA resin (0.2 g, 
0.52 mmol/g) by the same coupling strategy. After the removal of the terminal Nα-Fmoc 
protection, the trans-epoxysuccinyl group was attached to the pentapeptide chain by L- or D-
trans-epoxysuccinic acid using DIC and HOBt. The tripeptides as well as the epoxysuccinyl-
pentapeptides were removed from the resin by cleavage with 5 mL TFA containing 0.25 mL 
distilled water. In case of Trp containing tripeptide segments the cleavage was performed by 
TFA in the presence of scavengers (TFA, water, thioanisole, EDT, crystalline phenol = 5 mL, 
0.25 mL, 0.25 mL, 0.125 mL, 0.375 g). The crude product was precipitated by dry diethyl 
ether, dissolved in 10% acetic acid, freeze-dried and separated by RP-HPLC. Yield of peptide 
synthesis was 35-40%. 
 
2.2 Synthesis of epoxysuccinyl-nonapeptide analogues 
The purified epoxysuccinyl-pentapeptides and the tripeptides were coupled in solution 
(DMF). 10 mg (0.01 mmol) epoxysuccinyl-pentapeptide was reacted with 1.2 equivalent 
tripeptide in the presence of 1.2 equivalent DIC and HOBt. The reaction proceeded at RT 
overnight, then the DMF was evaporated and the components of the reaction mixture were 
separated by RP-HPLC. Yield of the conjugation reactions was 28-35%. 
 
2.3 RP-HPLC 
Analytical RP-HPLC was performed on a Zorbax SB C18 column (150x4.6mm I.D.) with 5 
µm silica (100 Å pore size) (Torrance, CA USA) as a stationary phase. A linear gradient 
elution was developed: 0 min 0% B; 2 min 0% B; 22 min 90% B with eluent A (0.1% TFA in 
water) and eluent B (0.1% TFA in acetonitrile-water (80: 20, v/v)). A flow rate of 1 mL/min 
was used at ambient temperature. Samples were dissolved in eluent B, injection volume: 20 
µL. Peaks were detected at λ = 220 nm. The purification of the crude products was carried out 
by RP-HPLC using Phenomenex Jupiter C18 column (250x10mm I.D.) with 10 µm silica 
(300 Å pore size) (Torrance, CA, USA), flow rate: 4 mL/min, room temperature. Linear 
gradient elution was applied. Gradient I: 0 min 5% B, 5 min 5% B, 50 min 50% B. Gradient 
II: 0 min 10% B, 5 min 10% B, 50 min 70% B. 
 
2.4 Amino acid analysis 
The amino acid composition of the peptides was determined by amino acid analysis 
performed on a Sykam Amino Acid S433H analyser (Eresing, Germany). Prior to analysis, 
samples were hydrolyzed with 6 M HCl in sealed and evacuated tubes at 110 °C for 24 h. 
 
2.5 Mass Spectrometry 
The peptides and peptide analogues were identified by electrospray ionization mass 
spectrometry (ESI-MS) on a Bruker Daltonics Esquire 3000 Plus (Bremen, Germany) ion trap 
mass spectrometer, operating in continuous sample injection at 4 µL/min flow rate. Samples 
were dissolved in ACN-water (50:50 v/v%) mixture containing 0.1 v/v% AcOH. Mass spectra 
were recorded in positive ion mode in the m/z 50-2000 range. 
 
2.6 Enzyme purification 
The 80-kDa large subunit and the 21-kDa truncated small subunit of rat calpain 2 were 
expressed in Escherichia coli as described earlier [22] and purified with Akta Explorer (GE 
Healthcare) fast protein liquid chromatography (FPLC) system, on a HisTrap HP column 
using step elution. Purified calpain 2 was dialyzed against 10 volume of calpain buffer (10 
mM HEPES, 150 mM NaCl, 1 mM EDTA, pH = 7.5). The enzyme preparation in solution 
was stored at 4 °C until use. 
 
2.7 Enzyme Inhibition Assay 
Activity of the enzymes (calpain 1 and 2, cathepsin B) was measured using a Synergy 
microplate reader, on a 96-well plate. In case of the calpains, the reaction mixture contained 
100 µM Suc-LY-AMC (Sigma) substrate, 3 mM Ca2+ and the inhibitor at various 
concentrations in 50 µl of calpain buffer. The reaction was initiated by adding and mixing 
rapidly 0.2 µM calpain 2 or 0.5 µM calpain 1. The cathepsin B activity was measured in 50 µl 
of 0.25 mM MES buffer (pH = 5.0) containing 100 µM cathepsin B substrate III and inhibitor 
at various concentrations. The reaction was started by adding and mixing rapidly 0.7 nM 
cathepsin B. Cathepsin B was activated in 0.25 mM MES buffer containing 10 mM DTE. The 
enzyme activity was followed by the change of fluorescence intensity measured at 
excitation/emission wavelengths of λ = 380/460 nm. Three replicates of each experiment were 
performed. The kinetic data were obtained from the pre-steady-state phase of the progress 
curve as described previously, accepting the method of previous authors for calculation of 
their epoxy-dipeptide inhibitors [19, 23, 24]. 
 
2.8 Molecular Modeling 
A model structure for the calpain 2 complex with inhibitor 2 and 11 was built. Starting 
structure was derived from the crystal structure of the calpain 2 – calpastatin complex [25], 
using domains II and III of the large catalytic unit, fitting both inhibitors to the calpastatin 
active region (612-613) in two opposing orientations, resulting in 4 different arrangements. 
The mutated catalytic residue (Ser105) was re-mutated in silico to its wild type equivalent of 
Cys. Monte Carlo Multiple Minimum (MCMM) searches were carried out by involving  the 
random variation (within the range of 0-180°) of a randomly selected subset of all torsional 
angles of the inhibitor, and the random translation (0-5 Å) and rotation (0-180°) of the 
inhibitor within the enzyme matrix in a Monte Carlo step. The perturbed structures were 
energy-minimized and the unique structures were stored within a 40 kJ/mol energy window 
above the global minimum. Calculations were carried out using the OPLS 2005 forcefield 
[26]. Solvent-effect was modeled by the GB/SA algorithm (using water solvent).  The first 
search of 3000 steps was restrained, where the distance of the SG atom of Cys105 and C2 and 
C3 of the epoxy-ring was held between 2.9-5.5 Å using a flat-bottom constraint, while energy 
minimization was carried out on all inhibitor atoms and the side chain atoms of all residues 
reaching within 6 Å of the inhibitor. In a second calculation, 1000 steps of constraint free 
MCMM search (Monte Carlo steps involving the inhibitor, but energy minimization carried 
out on the entire structure) was conducted on the lowest energy arrangement of each 
restrained search. The unbound inhibitors were also subject to 10000 steps constraint-free 
MCMM search to be able to estimate the binding energy. 
 
3. Results 
3.1 Synthesis and chemical characterization of epoxysuccinyl-peptide analogues 
We demonstrated earlier that oligopeptides with 9-11 amino acid residues as calpain 
inhibitors can be identified based on an 11-mer calpain substrate sequence (TPLKSPPPSPR) 
[11]. In the group of previously published inhibitory peptides, lysine at position P1 was 
replaced with azaglycine [26]. Here we report on the design and synthesis of a novel group of 
oligopeptide analogues containing D- or L-trans-epoxysuccinyl-group (D-Eps, L-Eps) (Table 
1). In these 9-mer compounds of TPLKSPPPS sequence the Lys residue at position P1 was 
replaced by the epoxysuccinyl moiety. 
The synthesis of epoxysuccinyl-nonapeptide analogues, as outlined in Scheme 1, was 
carried out by the combination of the separate solid phase peptide synthesis of the two 
segments, and their conjugation in solution. The N-terminal tripeptide amide (P4-P2) as well as 
the N-epoxysuccinyl-pentapeptide amide (P1’-P5’) were prepared on Rink-amide MBHA solid 
phase using Fmoc/tBu strategy. The epoxysuccinyl group was attached to the N-terminal 
amino group of the pentapeptide on solid phase using L- or D-trans-epoxysuccinic acid. After 
removal from the resin, the purified free tripeptide amide and the purified epoxysuccinyl-
pentapeptide amide were conjugated in solution by in situ activation using DIC-HOBt 
coupling reagents. The epoxysuccinyl-nonapeptides were purified by semipreparative RP-
HPLC. It should be noted that no significant ring opening was observed in case of 
epoxysuccinyl-pentapeptide analogues during the cleavage from the resin by TFA in the 
presence of a small amount of water. The homogeneity of the purified compounds was 
characterized by analytical RP-HPLC (in Supplementary information), while the amino acid 
composition and primary structure were verified by ESI-MS (Table 1) and amino acid 
analysis (in Supplementary information). 
The common feature of this group of nonapeptide analogues is that the P4-P2 segment (e.g. 
H-Leu-Pro-Thr-NH2) as well as the pentapeptide unit (e.g. H-Ser-Pro-Pro-Pro-Ser-NH2) are 
attached with their N-terminal amino group to the epoxysuccinyl group, so all sequences have 
a C-N(epoxysuccinyl)N-C orientation in their structure. 
 
 
 Scheme 1. Outline of the synthesis strategy of epoxysuccinyl-peptide analogue 
 Table 1. Chemical characteristics of epoxysuccinyl-nonapeptides. 
 
a
 HPLC retention time; column: Zorbax SB C18 column (150 x 4.6mm I.D.) with 5 µm 
silica (100 Å pore size). Linear gradient elution: 0 min 0% B; 2 min 0% B; 22 min 90% B 
with eluent A (0.1% TFA in water), and eluent B (0.1% TFA in acetonitrile-water (80:20, 
v/v)); flow rate: 1 mL/min, ambient temperature. Peaks were detected at λ = 220 nm. 
b
 ESI-MS analysis was carried out on a Bruker Esquire 3000 plus (Germany). The sample 
was dissolved in acetonitrile-water (50:50, v/v), 0.1% acetic acid. 
 Compound Rt a (min.) M(cal.) Mb(meas.) 
1.    NH2-Thr-Pro-Leu-(L-Eps)-Ser-Pro-Pro-Pro-Ser-NH2 12.5 906.5 906.5 
2.    NH2-Thr-Trp-Leu-(L-Eps)-Ser-Pro-Pro-Pro-Ser-NH2 12.6 995.8 995.6 
3.    NH2-Thr-Ser-Leu-(L-Eps)-Ser-Pro-Pro-Pro-Ser-NH2 10.3 884.4 884.7 
4.    NH2-Thr-Pro-Thr-(L-Eps)-Ser-Pro-Pro-Pro-Ser-NH2 9.7 882.5 882.4 
5.    NH2-Thr-Pro-Val-(L-Eps)-Ser-Pro-Pro-Pro-Ser-NH2 10.7 892.7 892.6 
6.    NH2-Thr-Pro-Leu-(L-Eps)-Arg-Pro-Pro-Pro-Ser-NH2 11.1 976.0 976.7 
7.    NH2-Thr-Pro-Leu-(L-Eps)-Thr-Pro-Pro-Pro-Ser-NH2 11.0 921.8 921.5 
8.    NH2-Thr-Pro-Leu-(L-Eps)-Ser-Ser-Pro-Pro-Ser-NH2 12.0 896.5 896.5 
9.    NH2-Thr-Pro-Leu-(L-Eps)-Ser-Gln-Pro-Pro-Ser-NH2 10.8 937.5 937.5 
10.  NH2-Thr-Pro-Leu-(D-Eps)-Ser-Pro-Pro-Pro-Ser-NH2 10.9 906.5 906.7 
11.  NH2-Thr-Trp-Leu-(D-Eps)-Ser-Pro-Pro-Pro-Ser-NH2 13.2 995.8 995.7 
12.  NH2-Thr-Pro-Thr-(D-Eps)-Ser-Pro-Pro-Pro-Ser-NH2 9.1 882.5 882.7 
13.  NH2-Thr-Pro-Val-(D-Eps)-Ser-Pro-Pro-Pro-Ser-NH2 10.2 892.5 892.5 
14.  NH2-Thr-Ser-Leu-(D-Eps)-Ser-Pro-Pro-Pro-Ser-NH2 10.2 884.4 884.7 
15.  NH2-Thr-Pro-Leu-(D-Eps)-Arg-Pro-Pro-Pro-Ser-NH2 11.1 976.0 975.9 
16.  NH2-Thr-Pro-Leu-(D-Eps)-Thr-Pro-Pro-Pro-Ser-NH2 12.3 921.8 921.8 
17.  NH2-Thr-Pro-Leu-(D-Eps)-Ser-Ser-Pro-Pro-Ser-NH2 11.9 896.5 896.5 
18.  NH2-Thr-Pro-Leu-(D-Eps)-Ser-Gln-Pro-Pro-Ser-NH2 10.7 937.5 937.5 
 3.2 Inhibition of the activity of calpain 1 and 2 
The inhibitory potential of epoxysuccinyl-peptides was studied on calpain 1 and 2 using 
Suc-LY-AMC as substrate, and it was characterized by Ki values (Table 2). If there was no 
inhibition at 50 µM concentration, the Ki value was not calculated. 
Concerning the activity of epoxysuccinyl-peptides with L-Eps isomer on calpains, we found 
that compound 1 with the L-trans-epoxysuccinyl group had no effect on calpain 2 even at c = 
50 µM, but had moderate effect on calpain 1 (Ki=12.50 µM). Substitution of Pro at position 
P3 with Trp (2) or Ser (3) resulted in compounds with inhibitory activity on both calpain 2 
(Ki=4.05 and 14.3 µM, respectively) and calpain 1 (Ki=17.14 and 21.92 µM, respectively). 
The effect of replacement of Leu residue at position P2 with Thr (4) had not effect on the 
activity, while the presence of Val (5) resulted in a peptide analogue with moderate inhibitory 
effect only on calpain 2 (Ki=29.23 µM). Moderate activity on calpain 2 (Ki=17.86 µM) and 
also on calpain 1 (Ki=23.73 µM) was observed after incubation of the enzymes with 
compound 6 with Arg residue at position P1’. Compound 7 with Thr at position P1’ exhibited 
good, but not excellent effect on calpain 1 (Ki=8.38 µM). Compound with Ser or Thr at 
position P2’ (8 or 9) did not exhibit any activity against calpains. 
In order to study the effect of stereochemical orientation related to the presence of D-
epoxysuccinic group instead of the L-isomer, nonapeptides with D-isomer were also prepared 
and examined. Among this group of analogues only compounds 11 and 16 inhibited calpain 2 
(Ki=21.43 and 4.24 µM), and compounds 11, 14 and 15 inhibited calpain 1 (Ki=3.70, 30.84 
and 26.33 µM). 
 
3.3 Selectivity: inhibition of cathepsin B activity 
Compounds with D- or L-epoxysuccinyl-group were also studied for their inhibitory effect 
on cathepsin B. In both groups of nonapeptide analogues, we found compounds with ability to 
inhibit the activity of cathepsin B. Epoxysuccinyl-peptides (2) and (7) with L-Eps (Ki=5.00 
and 12.07 µM, respectively), and also compound 11 with D-Eps (Ki=4.45 µM) were active on 
cathepsin B (Table 2). 
Table 2. The inhibitory effect of epoxysuccinyl-peptides. 
 Compound Ki (µM) (SD)a 
calpain 2 
 
calpain 1 cathepsin B  
 
1 >50 b 12.50 (3.54) >50 
2.  4.05 (2.10) 17.14 (3.29) 5.00 (2.06) 
3.  14.30 (2.70) 21.92 (1.29) >50 
4. >100 >100 >100 
5.  29.23 (5.00) >50 >100 
6.  17.86 (2.45) 23.73(7.28) >50 
7.   >50 8.38 (0.06) 12.07 (3.02) 
8. >100 >100 >100 
9. >100 >100 >100 
10. >50 >100 >50 
11.   21.43 (1.07) 3.70 (0.60) 4.45 (1.79) 
12.   no data >100 no data 
13. >100 >50 >100 
14.  no data 30.84 (1.05) no data 
15.  >50 26.33 (1.44) >100 
16. 4.24 (1.85) >50 >50 
17. >100 >100 >100 
18.   >100 >100 >100 
aData represent the mean S.D. value of triplicate experiments. 
b>50, >100: the epoxysuccinyl-peptide did not inhibit the enzyme at 50 or 100 µM 
concentration. 
 
3.4 Molecular modeling 
Epoxysuccinyl inhibitors have been co-crystallized with calpain 1 (2nqg [18], 2nqi, 2nqg 
[18], 1tlo [27]), papain (1cvz [28]) and cathepsin B (1ito [29]) previously.  These crystal 
structures show the covalently linked product of the cleavage – the epoxy-ring open and 
relaxed into an open-chain conformation. However, no small molecular complexes of calpain 
2 have been, to date, determined. The calculations carried out here depict the pre-cleavage 
state of calpain 2 in complex with compound 2 (the most effective inhibitor identified) and 
compound 11 (its markedly less effective, stereochemical counterpart), in the rate limiting 
docked state, prior to the nucleophilic attack of Cys.  
Peptide NH2-Thr-Trp-Leu-(L-Eps)-Ser-Pro-Pro-Pro-Ser-NH2 (2) is oriented within the 
binding grove by 11 intermolecular H-bonds (see Figure 1): residues P2-P4 are linked to 
Lys61, Gly103, Glu193, Ser196 of domain II of the enzyme, the epoxysuccinyl part is bound 
by the amide nitrogen of Gly198, P1’ Ser by the carbonyl oxygen of Gly261 of domain II and 
the P5’ Ser by Asp425 and Met426 of domain III – it is thus bound in a conformation where 
not the P2 Leu, but the P1’ Ser is immersed in the S2 pocket. This is not so surprising, since 
the S2 pocket is lined by polar residues (Thr200, Thr201, Ser241, Glu339), whereby it is far 
from being an ideal docking site for Leu, and although the P1’ Ser is too short to reach these 
residues, it benefits from the polarized environment created by them. P2 Leu is stabilized by 















Figure 1. A. Binding of compound 2 (NH2-Thr-Trp-Leu-(L-Eps)-Ser-Pro-Pro-Pro-Ser-NH2) 
(shown in blue with non-polar hydrogen atoms omitted for clarity) to the substrate binding 
cleft of calpain 2 (orange surface). The corresponding segment of calpastatin is also shown as 
a ribbon (purple).  B. H-bond network formed by the binding of compound 2.  C. Overlay of 
compound 2 and compound 11 bound in opposing orientation. 
 
The energetically most favorable conformation of compound 11 is of reversed orientation. 
While the epoxysuccinyl part of the peptide analogue is stabilized by an H-bond from the 
backbone amide group of Gly198, just as in case of compound 2, the reversed orientation 
places the Leu residue in P2 position in the S2 pocket. The estimated binding energy for this 
complex, however, is 31 kJ/mol weaker than that of the calpain 2 – compound 2 complex. 
Binding mode of both inhibitors is canonical in the sense that the central, epoxysuccinyl 
part of the molecules is anchored in both cases by an H-bond between the carbonyl oxygen of 
the inhibitor and the backbone amide of Gly198. Gly198 (and the corresponding Gly208 of 
calpain 1, Gly66 of papain and Gly74 of cathepsin B) forms a similar H-bond with the 
carbonyl oxygen atom of the Leu at position P2 of calpastatin (3df0 [30], ltl9 [27]), or the 
epoxysuccinyl carbonyl oxygen of E64 (1tlo [27]), E64C (1ito [29]), WR18 (2nqg [18]), 
WR13 (2nqi [18]) or also of CLIK148 [28].   
 
4. Discussion and conclusions 
Over-activated calpain enzymes are involved in several pathological processes in cells. 
Identification of appropriate inhibitors (effective and selective) may lead compounds for the 
treatment of diseases associated with over-activation. Such inhibitors could also be useful in 
studying the function of calpains even in normal cells. Inhibitors capable to distinguish not 
only between different cysteine proteases, but calpain isoforms could be even more valuable. 
Our approach to develop selective calpain inhibitors is based on the analysis of the sequences 
of relevant protein substrates [11]. 
The most examined part of calpain inhibitors is the P4-P1 preference region [10]. Only few 
studies were reported on the preference of the primed site (P4’-P1’) of inhibitors. We have 
selected the epoxysuccinyl functional group as a suitable moiety to examine the effect of 
amino acids at primed and non-primed sites on the inhibitory activity and selectivity. This 
group has an important contribution to the inhibitory potency of a cysteine protease selective 
inhibitor, E-64 [16]. Therefore the incorporation of this functional moiety could result in 
compounds with selectivity against cysteine proteases. 
According to our knowledge, no reports were published so far in which the effect of 
simultaneous substitutions at both non-primed and primed binding sites were analyzed. We 
have designed and synthesized compounds with amino acid substitutions considering the 
substrate preference matrix [11]. Amino acids with the first, the second and the third highest 
score were incorporated into the substrate sequence, TPLKSPPPSPR. Guided by the results of 
our earlier study with a group of azaglycine substituted substrate peptides exhibiting 
inhibitory properties [14], we have prepared a limited set of the analogues for the present 
investigations. 
 
4.1 The effect of the replacement of Lys at position P1 by L/D-Eps, and the amino acid 
substitution on inhibitory activity 
As our data suggest, the replacement of Lys residue at position P1 with L-Eps in the 
substrate sequence resulted in selective calpain 1 inhibition, while the analogue containing D-
Eps did not have any activity. These findings are in agreement with the literature describing 
that the stereochemistry of the epoxy-group could also have an effect on the activity. The 
analysis of inhibitory activity of compounds with L- or D-Eps modified sequences showed 
difference between their potency and selectivity against enzymes, although compounds 2 and 
11 with the same amino acid composition possessed similar potency against calpain 1 and 2 as 
well as cathepsin B. It seems that the binding mode of these compounds makes inhibitory 
potency insensitive for the stereochemistry of the epoxysuccinyl group. While compound 16 
with D-Eps had a marked inhibitory activity exclusively against calpain 2, its analogue with 
L-Eps, compound 7, inhibited both calpain 1 and cathepsin B, but not calpain 2. 
Our results confirmed the findings of Courrier et al [18] that at position P2 the Leu residue 
was preferred. Although its substitution to Val (5) resulted in a moderate calpain 2 inhibitory 
activity, without inhibiting the other enzymes. Thr (4) did not result in inhibition in this 
position,  
The replacement of Pro in position P3 had dramatic effect on the inhibitory potency. In the 
L-series, substitution with Trp or Ser, compound 2 and 3 resulted in calpain 2 inhibitors. It 
should be noted that compound 2 with Trp was found to be the most active nonapeptide 
analogue. These changes at the same time decreased the inhibitory activity towards the 
calpain 1 enzyme, and only the Trp analogue (2) expressed cathepsin B inhibitory activity. 
Our observation about the preference of Trp residue at this position is also in harmony with 
findings in the literature [18]. Trp was the most preferred amino acid next to the Arg at this 
position, and Pro was one of the most unfavorable.. In the D-series, the substitutions had little 
effect on the inhibitory potency of the original sequence. Only the presence of Trp residue at 
position P3 (11) and of Thr at position P’1 (16) resulted in inhibitory activity. The former 
compound was active on all three enzymes (calpain 1 and 2, cathepsin B), while the latter was 
selective on calpain 2. The appearance of Thr residue at position P’1 in the L-Eps analogue (7) 
exhibited an opposite effect. This compound inhibited calpain 1 and cathepsin B, but not 
calpain 2. 
 
4.2 Comparison of the sequences of inhibitory peptide analogues with azaGly or L/D- 
Eps 
When the sequence of the peptide TPLKSPPPS was modified by incorporation of 
azaglycine instead of Lys, the compound inhibited both calpain 1 and 2 [14]; while the 
presence of L/D-Eps in this position resulted in no activity. These observations suggest that 
the binding mode of two the structures can be different. While the azaglycine modification 
preserved the manner of substrate binding, the incorporation of L- or D-Eps moiety had no 
such influence. There are two main differences between the structures of molecules with 
azaamino acid or with epoxysuccinyl group. Incorporation of an azaamino acid does not alter 
the length of the peptide backbone, while the presence of an epoxysuccinyl moiety increases 
the distance with an additional methylene group. The second (major) difference is in the 
orientation of amino acid side chains originating from the reverse order of amino acid 
residues. In case of azapeptides only N to C direction occurs in the peptide sequence.  In sharp 
contrast, in compounds with epoxysuccinyl group the orientation of the amide bonds in the 
“N-terminal” (P4-P2 direction) part is reverse. These differences between the azaGly and L-
Eps substituted analogues may result in markedly changed inhibitory activity even in case of 
an “identical” peptide sequence. 
 
4.3 Comparison of selectivity of inhibitory peptide analogues with L/D-Eps 
In order to study the selectivity of compounds described in this and earlier published papers 
[14], the inhibitory activity was studied not only on calpain 1 and 2, but also on cathepsin B. 
The calpain 1 and 2 enzymes are major, ubiquitous isoforms of calpain with similar substrate 
preferences [31]. In fact, as our data suggest, we have identified a specific calpain 2 inhibitor, 
compound NH2-Thr-Pro-Leu-(D-Eps)-Thr-Pro-Pro-Pro-Ser-NH2 (16) which exhibits at least 
11.8-fold selectivity over calpain 1. Another nonapeptide analogue, NH2-Thr-Pro-Leu-(L-
Eps)-Ser-Pro-Pro-Pro-Ser-NH2 (1) could inhibit calpain 1 with at least 4-fold selectivity.  
Here we also describe that the incorporation of the epoxysuccinyl moiety could result in 
compounds with cathepsin B selectivity.  The above mentioned calpain 1 and 2 selective 
inhibitors (1 and 16, respectively) are selective also over cathepsin B (4- and 11.8-fold, 
respectively). It is interesting to note that compounds with inhibitory activity against 
cathepsin B have also inhibited calpain 1 (compounds 2, 7, 11).  
Taken together, the results presented in this communication demonstrate that it is possible 
to design novel calpain inhibitory peptide analogues based on a substrate sequence by 
insertion of epoxysuccinyl moiety at position P1 even into a long, 9-mer sequence. It is also 
described that the inhibitory activity does not depend only on the amino acid sequence, but 
also on the stereochemical arrangement of the epoxysuccinyl group. This finding was further 
supported by the results of the molecular modeling studies suggesting that a change in the 
stereochemistry of the epoxysuccinyl group might reverse the orientation of the inhibitor 
within the substrate binding groove of calpain 2. Calculations also showed that specifically 
bound inhibitors could form a number of well-positioned H-bonds with the protein matrix 
including both side chain and main-chain contacts, originating from an extensive surface of 
the protein.  
Furthermore, with compounds 1 and 16 we could demonstrate that there is a possibility of 
developing selective calpain 1 and 2 inhibitors by the appropriate combination of 
epoxysuccinyl moiety, simultaneous extension of peptide parts at both sides, and topological 
considerations. Further studies should be performed to investigate the effect of these 
inhibitors on intracellular calpains. Based on our preliminary studies, these inhibitors are not 
taken up by cells, therefore in order to study their effect on intracellular enzymes cell-
penetrating conjugate derivatives will be prepared. 
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